WO2005086872A3 - Ptpn22 polymorphisms in diagnosis and therapy - Google Patents

Ptpn22 polymorphisms in diagnosis and therapy Download PDF

Info

Publication number
WO2005086872A3
WO2005086872A3 PCT/US2005/007800 US2005007800W WO2005086872A3 WO 2005086872 A3 WO2005086872 A3 WO 2005086872A3 US 2005007800 W US2005007800 W US 2005007800W WO 2005086872 A3 WO2005086872 A3 WO 2005086872A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorder
subjects
ptpn22
methods
cell proliferation
Prior art date
Application number
PCT/US2005/007800
Other languages
French (fr)
Other versions
WO2005086872A2 (en
Inventor
Samuel E Broder
Robert F Booth
Original Assignee
Celera An Applera Corp Busines
Samuel E Broder
Robert F Booth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celera An Applera Corp Busines, Samuel E Broder, Robert F Booth filed Critical Celera An Applera Corp Busines
Publication of WO2005086872A2 publication Critical patent/WO2005086872A2/en
Publication of WO2005086872A3 publication Critical patent/WO2005086872A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides 1) methods and compositions for detecting polymorphisms of the PTPN22 genomic DNA; 2) methods for associating polymorphisms of the PTPN22 gene with the occurrence of an immune disorder, inflammatory disorder or cell proliferation disorder; 3) methods for identifying subjects at risk of an immune disorder, inflammatory disorder or cell proliferation disorder by determining if they have a polymorphism of the PTPN22 gene and treating such subjects with a tyrosine kinase inhibitor to prevent or delay the progression of such diseases; 4) methods for identifying subjects having an immune disorder, inflammatory disorder or cell proliferation disorder who are promising candidates for therapy with a tyrosine kinase inhibitor by determining if such subjects have a polymorphism of the PTPN22 gene; and 5) methods of treating subjects having an immune disorder, inflammatory disorder or cell proliferation disorder mediated by a polymorphism of the PTPN22 gene by administering to such subjects a tyrosine kinase inhibitor.
PCT/US2005/007800 2004-03-10 2005-03-08 Ptpn22 polymorphisms in diagnosis and therapy WO2005086872A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55221604P 2004-03-10 2004-03-10
US60/552,216 2004-03-10

Publications (2)

Publication Number Publication Date
WO2005086872A2 WO2005086872A2 (en) 2005-09-22
WO2005086872A3 true WO2005086872A3 (en) 2006-03-09

Family

ID=34976203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/007800 WO2005086872A2 (en) 2004-03-10 2005-03-08 Ptpn22 polymorphisms in diagnosis and therapy

Country Status (1)

Country Link
WO (1) WO2005086872A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010146A2 (en) * 2004-07-09 2006-01-26 The Burnham Institute Functional variant of lymphoid tyrosine phosphatase is associated with autoimmune disorders
GB0613844D0 (en) * 2006-07-12 2006-08-23 Progenika Biopharma Sa Methods and products for in vitro genotyping
AR065910A1 (en) * 2007-04-02 2009-07-08 Genentech Inc FORECAST BIOLOGICAL MARKERS OF THE RESPONSE OF THE Rheumatoid ARTHRITIS TO THE ANTAGONISTS OF THE LYMPHOCYTES B
RU2009147281A (en) * 2007-05-21 2011-06-27 Дженентек, Инк. (Us) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF LUPUS
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2486152B1 (en) 2009-10-07 2017-12-06 F. Hoffmann-La Roche AG Methods for diagnosing lupus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006777A1 (en) * 1998-01-16 2004-01-08 Hsc Research And Development Limited Partnership Human lymphoid protein tyrosine phosphatases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006777A1 (en) * 1998-01-16 2004-01-08 Hsc Research And Development Limited Partnership Human lymphoid protein tyrosine phosphatases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEGOVIC A.B. ET AL: "A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22)is associated with Rheumatoid Arthritis", AM. J. HUM. GENET., vol. 75, no. 2, August 2004 (2004-08-01), pages 330 - 337, XP002994749 *
STEEL R.S. ET AL: "Association between stromal cell-derived factor 1 chemokine gene variant and radiographic progression of rheumatoid arthritis", ARTHRITIS & RHEUMATISM., vol. 52, no. 1, 1 January 2005 (2005-01-01), pages 354 - 360, XP002994750 *

Also Published As

Publication number Publication date
WO2005086872A2 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
Pirmohamed Personalized pharmacogenomics: predicting efficacy and adverse drug reactions
Aran et al. Widespread parainflammation in human cancer
WO2009059317A3 (en) Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
WO2005086872A3 (en) Ptpn22 polymorphisms in diagnosis and therapy
WO2007038670A3 (en) Methods and compositions for screening and treatment of disorders of blood glucose regulation
WO2008088893A3 (en) Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy
Kim et al. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
SI1730315T1 (en) Polymorphisms in nod2/card15 gene
WO2008089465A3 (en) Gene polymorphisms as sex-specific predictors in cancer therapy
WO2006060265A3 (en) Methods and systems for prognosis and treatment of solid tumors
WO2008088861A3 (en) Gene polymorphisms predictive for dual tki therapy
WO2008017002A3 (en) Polymorphisms in genes affecting cns disorders and uses thereof
WO2009149026A3 (en) Genomic approaches to fetal treatment and diagnosis
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
WO2007058968A3 (en) Gene expression profiles and methods of use
WO2005059108A3 (en) Gene expression profiles and methods of use
Zhou et al. A miR-1231 binding site polymorphism in the 3′ UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility
Qin et al. Association of IRF5 gene polymorphisms and lupus nephritis in a Chinese population
WO2004101806A3 (en) Allele-specific expression patterns
WO2009062166A3 (en) Dna microarray based identification and mapping of balanced translocation breakpoints
WO2005032495A3 (en) Gene expression profiles and methods of use
WO2007124309A3 (en) Methods for detecting mutations in jak2 nucleic acid
O’Connor et al. IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis
Sun et al. Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase